Compare FLYW & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | IOVA |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | 2008 |
| Metric | FLYW | IOVA |
|---|---|---|
| Price | $13.64 | $3.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $16.21 | $9.00 |
| AVG Volume (30 Days) | 1.5M | ★ 14.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | 14.84 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $623,025,000.00 | N/A |
| Revenue This Year | $19.68 | $47.74 |
| Revenue Next Year | $15.25 | $40.31 |
| P/E Ratio | $123.05 | ★ N/A |
| Revenue Growth | ★ 26.59 | N/A |
| 52 Week Low | $9.05 | $1.64 |
| 52 Week High | $15.25 | $5.63 |
| Indicator | FLYW | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 62.43 | 45.56 |
| Support Level | $13.30 | $2.05 |
| Resistance Level | $14.04 | $4.33 |
| Average True Range (ATR) | 0.52 | 0.29 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 83.57 | 21.23 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.